Author:
Kim Jinhyun,Park Kyung Mee,Lee Suonaa,Park Sooji,Hong Minji,Shin Jaeyong,Lee Eun
Abstract
Abstract
Background
Digital therapeutics (DTx) is a treatment option that uses computer software to provide evidence-based interventions for medical disorders. DTx platforms are digital services that facilitate interactions among stakeholders of DTx treatment within a standardized structure. However, there is still a lack of overall awareness regarding the effectiveness and usage of DTx and DTx platforms. This study aimed to investigate insomnia patients’ recognition, thoughts, feelings, and demands for conventional treatments versus DTx for insomnia.
Methods
Nine participants, aged 19–50 years, who had experience with professional medical interventions for insomnia, were recruited through purposive sampling. Two online focus group interviews, each lasting 1.5 h, were conducted. The interview questions focused on difficulties encountered during conventional treatment, inadequate recognition of DTx, and concerns and demands regarding DTx and its platform. The data were analyzed using thematic analysis.
Results
The participants reported subjective difficulties associated with receiving conventional treatment, including concerns about drug side effects and dependence, social stigma, and lack of perceived necessity for treatment. They expressed concerns about DTx, such as cost-effectiveness, evidence on efficacy, and concerns about breach of personal information. Additionally, their demands included convenience of use, reduction in social stigma related to the use of DTx, compatibility of DTx with other healthcare systems, and enhanced communication with healthcare providers when using DTx platforms.
Conclusions
The focus group highlighted the need for increased awareness, demonstrated efficacy, cost-effectiveness, cybersecurity measures, and accessibility of insomnia DTx and its platforms. Tailored approaches considering patient characteristics are crucial for widespread adoption of insomnia DTx and its platforms.
Funder
Ministry of Trade, Industry and Energy
Publisher
Springer Science and Business Media LLC
Reference37 articles.
1. Digital Therapeutics Alliance. Understanding DTx. 2018. https://dtxalliance.org/understanding-dtx/April 25, 2023.
2. European Data Protection Supervisor. Digital Therapeutics (DTx). 2017. https://edps.europa.eu/press-publications/publications/techsonar/digital-therapeutics-dtx_enApril 25, 2023.
3. Wang C, Lee C, Shin H. Digital therapeutics from bench to bedside. NPJ Digit Med. 2023;6(1):38.
4. Hong JS, Wasden C, Han DH. Introduction of digital therapeutics. Comput Methods Programs Biomed. 2021;209:106319.
5. Ministry of Food and Drug Safety (MFDS) of the Republic of Korea. Digital Therapeutics (DTx) Bring about Wider Treatment Options and Improved Convenience. 2023. https://www.mfds.go.kr/eng/brd/m_61/view.do?seq=142April 25, 2023.